Products with Anti-proliferation bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN6331 | Isoliensinine |
| Isoliensinine has anti-cancer, anti-fibrosis, anti-proliferative, antioxidant, and anti-inflammatory activities, it inhibited TNF-alpha and TGF-beta 1; decreased the overexpression of growth factors Platelet-derived growth factor (PDGF)-beta, basic fibroblast growth factor (bFGF), proto-oncogene c-fos, c-myc and hsp70; and activated ROS and p38 MAPK/JNK . | |
| BCN6434 | Notoginsenoside Ft1 |
| 1. Notoginsenoside Ft1 may accelerate diabetic wound healing by orchestrating multiple processes, including promoting fibroblast proliferation, enhancing angiogenesis, and attenuating inflammatory response, which provided a great potential application of it in clinics for patients with diabetic foot ulcers. 2. Notoginsenoside Ft1 can arrest the proliferation and elicited the apoptosis of SH-SY5Y cells possibly via p38 MAPK and ERK1/2 pathways, which indicates the potential therapeutic effect of it on human neuroblastoma. 3. Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. 4. Notoginsenoside Ft1 can enhance platelet aggregation by activating a signalling network mediated through P2Y₁₂ receptors. 5. Notoginsenoside Ft1 is a novel stimulator of angiogenesis, it stimulates angiogenesis via HIF-1α-mediated VEGF expression, with PI3K/AKT and Raf/MEK/ERK signaling cascades concurrently participating in the process. | |
| BCN6483 | Epimedokoreanin B |
| 1. Epimedokoreanin B can significantly inhibit the formation of both N (ε) -(carboxymethyl)lysine (CML) and N (ω) -(carboxymethyl)arginine (CMA), it may prevent clinical complications of diabetes by inhibiting advanced glycation end-products (AGEs). 2. Epimedokoreanin B shows scavenge the DPPH radical activity. 3. Epimedokoreanin B can inhibit the proliferation of MCF-7 and HepG2 in dose-dependant manner. | |
| BCN6501 | Euphohelioscopin A |
| 1. Euphohelioscopin A exhibits moderate inhibitory activity on the release of cytokine TNF-α (IC50 = 23.7 ± 1.7 uM), IL-6 (IC50 = 46.1 ± 1.1 uM) and chemokine MCP-1 (IC50 = 33.7 ± 3.8 uM) in lipopolysaccharide (LPS) induced RAW 264.7 macrophages without notable cytotoxicity (IC50 > 80 uM). 2. Euphohelioscopin A, an activator of protein kinase C (PKC), it inhibits proliferation and induces differentiation of the myeloid leukemia cell lines THP-1 and HL-60. | |
| BCN6657 | Sprengerinin C |
| 1. Sprengerinin C can strongly suppress tumor angiogenesis in human umbilical vein endothelial cells, it blocks vascular endothelial growth factor receptor 2-dependent phosphoinositide 3-kinase/Akt/mTOR/matrix metalloproteinase and p38 MAPK/matrix metalloproteinase pathways,two major pathways for tumor angiogenesis; sprengerinin C also can induce HepG-2/BEL7402 cell apoptosis by activating NADPH oxidase/reactive oxygen species-dependent caspase apoptosis pathway and suppress HepG-2/BEL7402 cell growth through p53-mediated G2/M-phase arrest, suggests that sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis. | |
